KNOLL MERIDIA STUDIES CONTINUE AFTER REDUX, PONDIMIN WITHDRAWAL; LAWSUITS CALL FOR WYETH TO FUND MEDICAL MONITORING OF PATIENTS EXPOSED TO DRUGS
Executive Summary
Knoll has not halted any ongoing studies of its "approvable" obesity therapy Meridia (sibutramine) following Wyeth-Ayerst's withdrawal of its obesity drugs Redux (dexfenfluramine) and Pondimin (fenfluramine), the company said.